| Brand (fictional) | Therapy  | Net Sales (â‚¹ cr)  | YoY Growth  |  Gross Margin % | Promo Intensity (Promo as % of sales) | Comment |
| ------------- | ------------- | ------------- | ------------- | ------------- | ------------- | ------------- | 
| Ceforid  | Anti-infective | 21.0 | +6% | 64% | 9% | Competitive crowding; trade pressure rising |
| Painrel  | Pain mgmt | 14.0 | +9% | 68% | 8% |Strong prescriber loyalty in 4 states |
| Moxid  | Anti-infective | 12.0 | +3% | 61% | 10% | Tender spillover affects retail pricing |
| Nurofenac  | Pain mgmt | 9.5 | +12% | 70% | 7% | Mix improving toward higher margin packs |
| Gastrozil  | Gastro | 8.0 | +8% | 66% | 6% | Stable; low noise |
| VitaSure  | Vitamins | 6.5 | +15% | 58% | 12% | Growth is spendled; durability unclear |
| Dermacare | Derma | 6.0 | +5% | 72% | 6% | Small but profitable |
| Other Brands  | Mixed | 41.5 | +7% | 60% | 8% | Long tail; many low-focus SKUs |
| Total  |  | 118.5 | +9% |  |  |  |

